Pharmacokinetic and Pharmacodynamic Study of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Positive Patients
Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to determine the PK (tesamorelin) and PD (IGF-1)
profiles of tesamorelin after a single 2 mg subcutaneous administration and after repeated
administration once daily for 14 consecutive days. Secondary objectives include the
evaluation of the safety and tolerability of tesamorelin following multiple subcutaneous
injections.